.jpg)
The MHRA received official confirmation in early November 2013 that the European Agency for Health and Consumers (EAHC), an executive agency of the European Commission, had approved funding for SCOPE. The key objective of the project is to enable the National Competent Authorities in member states to move from implementation of the requirements of the new pharmacovigilance legislation to truly operating those requirements to the highest possible standards against agreed benchmarks and best practice.
To formally launch SCOPE the MHRA arranged a workshop held at the EAHC in Luxembourg on 18 November 2013, which was attended by 40 delegates from 26 countries and institutions. The workshop provided an excellent opportunity to discuss topics such as adverse drug reaction reporting, signal detection and risk communications to inform, enthuse, and motivate the participating member states. It was an excellent opportunity to bring all the SCOPE partners together in order to foster an atmosphere of mutual cooperation and collaboration for the greater good of the Joint Action.
Image above – SCOPE launch workshop presentations – left to right: Mick Foy (WP1 and 2, MHRA), June Raine (General Advisory Board, PRAC) and Viola Macolić-Šarinić (WP4, HALMED)
Delegates at the SCOPE Launch Workhop in Luxembourg
